The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Quality-of ...

Discover how 18F-FDG PET and PET/CT provide critical diagnostic accuracy for detecting high-grade transformations in chronic ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

4,6 It is notable that this patient did not have any obvious masses or radiologic or cytologic abnormalities to initially suggest leukemia or lymphoma, despite a chronic and severe clinical ...